Skip to main content
. 2020 May 8;43(5):1060–1069. doi: 10.1002/jimd.12245

TABLE 2.

Description of crude death rates for miglustat‐treated vs untreated patients

Patients in the miglustat‐treated period a Patients in the miglustat‐untreated period b
Age‐at‐neurological‐onset sub‐group No. of patients in the analysis, n Total PY Death rate (per 100 PY) No. (%) of patients who died No. of patients in the analysis, n Total PY Death rate (per 100 PY) No (%) of patients who died
Neurological onset group
All ages 353 942.9 5.51 52 (14.7) 406 3174.8 5.61 178 (43.8)
Early infantile (<2 years) 43 88.9 21.37 19 (44.2) 65 226.3 11.93 27 (41.5)
Late infantile (2 to <6 years) 96 247.5 5.25 13 (13.5) 139 1016.6 7.87 80 (57.6)
Juvenile (6 to <15 years) 108 320.8 2.81 9 (8.3) 111 1035.8 4.54 47 (42.3)
Adolescent/adult (≥15 years) 106 285.7 3.85 11 (10.4) 91 896.2 2.68 24 (26.4)
Diagnosis group
All ages 307 880.8 5.56 49 (16.0) 353 1846.3 9.42 174 (49.3)
Early infantile (<2 years) 38 82.2 20.67 17 (44.7) 60 161.5 16.72 27 (45.0)
Late infantile (2 to <6 years) 88 239.7 5.42 13 (14.8) 136 706.6 11.04 78 (57.4)
Juvenile (6 to <15 years) 91 298.2 2.68 8 (8.8) 100 647.3 7.26 47 (47.0)
Adolescent/adult (≥15 years) 90 260.6 4.22 11 (12.2) 57 330.8 6.65 22 (38.6)
a

Patients received miglustat at any time.

b

Patients either never received miglustat or were initially untreated after their onset of neurological manifestations.

Abbreviation: PY, patient‐years.